Atlas Trials

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Clinical trial NCT05397639 · RECRUITING

Trial details

NCT number
NCT05397639
Sponsor
Suven Life Sciences Limited
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
AgitationAlzheimer's Type Dementia
Start date
2022-11-01
Primary completion
2026-12-01
Enrollment
375

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.